{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T12:13:48Z","timestamp":1783944828971,"version":"3.55.0"},"reference-count":47,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,9,3]],"date-time":"2020-09-03T00:00:00Z","timestamp":1599091200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.ad.2020.08.003","type":"journal-article","created":{"date-parts":[[2020,9,6]],"date-time":"2020-09-06T01:45:41Z","timestamp":1599356741000},"page":"14-23","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Linfomas cut\u00e1neos. Parte I: micosis fungoide, s\u00edndrome de S\u00e9zary y proliferaciones linfoides cut\u00e1neas CD30 positivas"],"prefix":"10.1016","volume":"112","author":[{"given":"R.M.","family":"Pujol","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Gallardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ad.2020.08.003_bib0240","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2018-11-881268","article-title":"The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas","volume":"133","author":"Willemze","year":"2019","journal-title":"Blood."},{"key":"10.1016\/j.ad.2020.08.003_bib0245","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1001\/jamadermatol.2013.5526","article-title":"Changing incidence trends of cutaneous T-cell lymphoma","volume":"149","author":"Korgavkar","year":"2013","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.ad.2020.08.003_bib0250","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jaad.2013.08.033","article-title":"Primary cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome): Part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers","volume":"70","author":"Jawed","year":"2014","journal-title":"J Am Acad Dermatol."},{"issue":"Suppl. 6","key":"10.1016\/j.ad.2020.08.003_bib0255","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1093\/annonc\/mdt242","article-title":"Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"24","author":"Willemze","year":"2013","journal-title":"Ann Oncol."},{"key":"10.1016\/j.ad.2020.08.003_bib0260","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1182\/blood-2008-04-152850","article-title":"European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas","volume":"112","author":"Senff","year":"2008","journal-title":"Blood."},{"key":"10.1016\/j.ad.2020.08.003_bib0265","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood."},{"key":"10.1016\/j.ad.2020.08.003_bib0270","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1182\/blood-2007-03-055749","volume":"110","author":"Olsen","year":"2007","journal-title":"Blood."},{"key":"10.1016\/j.ad.2020.08.003_bib0275","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1182\/blood-2006-10-054601","volume":"110","author":"Kim","year":"2007","journal-title":"Blood."},{"key":"10.1016\/j.ad.2020.08.003_bib0280","doi-asserted-by":"crossref","first-page":"4730","DOI":"10.1200\/JCO.2009.27.7665","article-title":"Survival outcomes and prognostic factors in mycosis fungoides\/Sezary syndrome: validation of the revised International Society for Cutaneous Lymphomas\/European Organisation for Research and Treatment of Cancer staging proposal","volume":"28","author":"Agar","year":"2010","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.ad.2020.08.003_bib0285","doi-asserted-by":"crossref","first-page":"3766","DOI":"10.1200\/JCO.2015.61.7142","article-title":"Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and S\u00e9zary Syndrome: Effect of specific prognostic markers on survival and development of a prognostic model","volume":"33","author":"Scarisbrick","year":"2015","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.ad.2020.08.003_bib0290","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.clml.2012.01.011","article-title":"Pilot study of denileukin diftitox alternate dosing regimen in patients with cutaneous peripheral T-cell lymphomas","volume":"12","author":"Talpur","year":"2012","journal-title":"Clin Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.ad.2020.08.003_bib0295","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1038\/ng.3356","article-title":"Genomic landscape of cutaneous T cell lymphoma","volume":"47","author":"Choi","year":"2015","journal-title":"Nat Genet."},{"key":"10.1016\/j.ad.2020.08.003_bib0300","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1038\/ng.3442","article-title":"The mutational landscape of cutaneous T cell lymphoma and S\u00e9zary syndrome","volume":"47","author":"Da Silva Almeida","year":"2015","journal-title":"Nat Genet."},{"key":"10.1016\/j.ad.2020.08.003_bib0305","doi-asserted-by":"crossref","first-page":"8470","DOI":"10.1038\/ncomms9470","article-title":"Genomic analyses reveal recurrent mutations in epigenetic modifiers and the JAK-STAT pathway in Sezary syndrome","volume":"6","author":"Kiel","year":"2015","journal-title":"Nate Commun."},{"key":"10.1016\/j.ad.2020.08.003_bib0310","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1182\/blood-2014-11-611194","article-title":"Whole-genome sequencing reveals oncogenic mutations in mycosis fungoides","volume":"126","author":"McGirt","year":"2015","journal-title":"Blood."},{"key":"10.1016\/j.ad.2020.08.003_bib0315","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1182\/blood-2013-05-504308","article-title":"PLCG1 mutations in cutaneous T-cell lymphomas","volume":"123","author":"Vaque","year":"2014","journal-title":"Blood."},{"key":"10.1016\/j.ad.2020.08.003_bib0320","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1038\/ng.3444","article-title":"Genomic profiling of S\u00e9zary syndrome identifies alterations of key T cell signaling and differentiation genes","volume":"47","author":"Wang","year":"2015","journal-title":"Nat Genet."},{"key":"10.1016\/j.ad.2020.08.003_bib0325","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1016\/j.jid.2016.03.024","article-title":"Identification of gene mutations and fusion genes inpatients with S\u00e9zary Syndrome","volume":"136","author":"Prasad","year":"2016","journal-title":"J Invest Dermatol."},{"key":"10.1016\/j.ad.2020.08.003_bib0330","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1016\/j.jid.2018.06.176","article-title":"An integrated data resource for genomic analysis of cutaneous T-cell lymphoma","volume":"138","author":"Chang","year":"2018","journal-title":"J Invest Dermatol."},{"key":"10.1016\/j.ad.2020.08.003_bib0335","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1182\/blood-2017-02-768234","article-title":"Genomic analysis of 220 CTCLs identifies a novel recurrent gain-of-function alteration in RLTPR (p.Q575E)","volume":"130","author":"Park","year":"2017","journal-title":"Blood."},{"key":"10.1016\/j.ad.2020.08.003_bib0340","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.jaad.2009.03.014","article-title":"Folliculotropic mycosis fungoides: clinicopathological features and outcome in a series of 20 cases","volume":"62","author":"Muniesa","year":"2010","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.ad.2020.08.003_bib0345","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1001\/jamadermatol.2016.1597","article-title":"Clinical staging and prognostic factors in folliculotropic mycosis fungoides","volume":"152","author":"Van Santen","year":"2016","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.ad.2020.08.003_bib0350","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jaad.2013.08.033","article-title":"Primary cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome): Part II. Prognosis, management, and future directions","volume":"70","author":"Jawed","year":"2014","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.ad.2020.08.003_bib0355","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ejca.2017.02.027","article-title":"European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides\/S\u00e9zary syndrome - Update 2017","volume":"77","author":"Trautinger","year":"2017","journal-title":"Eur J Cancer."},{"key":"10.1016\/j.ad.2020.08.003_bib0360","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jaad.2015.09.033","article-title":"Guidelines for phototherapy of mycosis fungoides and Sezary syndrome: a consensus statement of the United States Cutaneous Lymphoma Consortium","volume":"74","author":"Olsen","year":"2016","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.ad.2020.08.003_bib0365","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1001\/2013.jamadermatol.541","article-title":"Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides","volume":"149","author":"Lessin","year":"2013","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.ad.2020.08.003_bib0370","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S0190-9622(03)01475-0","article-title":"Topical bexarotene therapy for patients with refractory or persistent early-stage cutaneous T-cell lymphoma: results of the phase III clinical trial","volume":"49","author":"Heald","year":"2003","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.ad.2020.08.003_bib0375","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1182\/blood-2015-02-630335","article-title":"Topical resiquimod can induce disease regression and enhance T-cell effector functions in cutaneous T-cell lymphoma","volume":"126","author":"Rook","year":"2015","journal-title":"Blood."},{"key":"10.1016\/j.ad.2020.08.003_bib0380","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1200\/JCO.2001.19.9.2456","article-title":"Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results","volume":"19","author":"Duvic","year":"2001","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.ad.2020.08.003_bib0385","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1396-0296.2003.01643.x","article-title":"Interferon in the treatment of cutaneous T-cell lymphoma","volume":"16","author":"Olsen","year":"2003","journal-title":"Dermatol Ther."},{"key":"10.1016\/j.ad.2020.08.003_bib0390","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1067\/mjd.2002.123482","article-title":"Total skin electron radiation in the management of mycosis fungoides: consensus of the EORTC Cutaneous Lymphoma Project Group","volume":"47","author":"Jones","year":"2002","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.ad.2020.08.003_bib0395","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/j.1396-0296.2003.01647.x","article-title":"Mycosis fungoides: radiation therapy","volume":"16","author":"Hoppe","year":"2003","journal-title":"Dermatol Ther."},{"key":"10.1016\/j.ad.2020.08.003_bib0400","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.jaad.2014.10.014","article-title":"Low-dose total skin electron beam therapy as an effective modality to reduce disease burden in patients with mycosis fungoides: results of a pooled analysis from 3 phase-II clinical trials","volume":"72","author":"Hoppe","year":"2015","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.ad.2020.08.003_bib0405","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/bjd.15355","article-title":"Recommendations for treatment in folliculotropic mycosis fungoides: report of the Dutch Cutaneous Lymphoma Group","volume":"177","author":"Van Santen","year":"2017","journal-title":"Br J Dermatol."},{"key":"10.1016\/j.ad.2020.08.003_bib0410","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1007\/s00277-014-2121-1","article-title":"Long-term outcome of patients with advanced-stage cutaneous T cell lymphoma treated with gemcitabine","volume":"93","author":"Pellegrini","year":"2014","journal-title":"Ann Hematol."},{"key":"10.1016\/j.ad.2020.08.003_bib0415","doi-asserted-by":"crossref","first-page":"4091","DOI":"10.1200\/JCO.2011.39.8065","article-title":"Prospective international multicenter phase II trial of intravenous pegylated liposomal doxorubicin monochemotherapy in patients with stage IIB, IVA, or IVB advanced mycosis fungoides: final results from EORTC 21012","volume":"30","author":"Dummer","year":"2012","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.ad.2020.08.003_bib0420","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.det.2015.05.010","article-title":"Histone deacetylase inhibitors for cutaneous T-cell lymphoma","volume":"33","author":"Duvic","year":"2015","journal-title":"Dermatol Clin."},{"key":"10.1016\/j.ad.2020.08.003_bib0425","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0140-6736(17)31266-7","article-title":"Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial","volume":"390","author":"Prince","year":"2017","journal-title":"Lancet."},{"key":"10.1016\/j.ad.2020.08.003_bib0430","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/S1470-2045(18)30379-6","article-title":"Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial","volume":"19","author":"Kim","year":"2018","journal-title":"Lancet Oncol."},{"issue":"Suppl 1","key":"10.1016\/j.ad.2020.08.003_bib0435","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/jdv.12311","article-title":"Guidelines on the use of extracorporeal photopheresis","volume":"28","author":"Knobler","year":"2014","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"10.1016\/j.ad.2020.08.003_bib0440","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1111\/bjd.12690","article-title":"Long-term efficacy and safety of alemtuzumab in advanced primary cutaneous T-cell lymphomas","volume":"170","author":"De Masson","year":"2014","journal-title":"Br J Dermatol."},{"key":"10.1016\/j.ad.2020.08.003_bib0445","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.det.2015.05.014","article-title":"Hematopoietic stem cell transplantation for mycosis fungoides and S\u00e9zary syndrome","volume":"33","author":"Virmani","year":"2015","journal-title":"Dermatol Clin."},{"key":"10.1016\/j.ad.2020.08.003_bib0450","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1182\/blood.V128.22.181.181","article-title":"Pembrolizumab for treatment of relapsed\/refractory mycosis fungoides and Sezary syndrome: clinical efficacy in a CITN multicenter phase 2 study","volume":"128","author":"Khodadoust","year":"2016","journal-title":"Blood."},{"key":"10.1016\/j.ad.2020.08.003_bib0455","doi-asserted-by":"crossref","first-page":"4024","DOI":"10.1182\/blood-2011-05-351346","article-title":"EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma","volume":"118","author":"Kempf","year":"2011","journal-title":"Blood."},{"key":"10.1016\/j.ad.2020.08.003_bib0460","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1097\/PAS.0b013e3181e75356","article-title":"A variant of lymphomatoid papulosis simulating primary cutaneous aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma. Description of 9 cases","volume":"34","author":"Saggini","year":"2010","journal-title":"Am J Surg Pathol."},{"key":"10.1016\/j.ad.2020.08.003_bib0465","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/PAS.0b013e3182648596","article-title":"Angioinvasive lymphomatoid papulosis: a new variant simulating aggressive lymphomas","volume":"37","author":"Kempf","year":"2013","journal-title":"Am J Surg Pathol."},{"key":"10.1016\/j.ad.2020.08.003_bib0470","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1097\/PAS.0b013e318282d01e","article-title":"Chromosomal rearrangements of 6p25.3 define a new subtype of lymphomatoid papulosis","volume":"37","author":"Karai","year":"2013","journal-title":"Am J Surg Pathol."}],"container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731020303070?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731020303070?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T01:11:00Z","timestamp":1757553060000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001731020303070"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["S0001731020303070"],"URL":"https:\/\/doi.org\/10.1016\/j.ad.2020.08.003","relation":{},"ISSN":["0001-7310"],"issn-type":[{"value":"0001-7310","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Linfomas cut\u00e1neos. Parte I: micosis fungoide, s\u00edndrome de S\u00e9zary y proliferaciones linfoides cut\u00e1neas CD30 positivas","name":"articletitle","label":"Article Title"},{"value":"Actas Dermo-Sifiliogr\u00e1ficas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ad.2020.08.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 AEDV. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}